Getting your Trinity Audio player ready...
LyphoMed Inc. said its directors declared a 3-for-2 split of the company`s common stock. Shareholders of record March 18 will receive one additional share for each two shares held. LyphoMed had about 6.7 million common shares outstanding March 1 and said the split will boost the total to a little more than 10 million. John N. Kapoor, chairman of the Melrose Park-based pharmaceutical firm, said the split reflects the company`s favorable fortunes and will help provide ”a more liquid market for the stock” as demand increases.
